Morgan Stanley has raised its price target for Ultragenyx Pharmaceutical (NASDAQ: RARE) to $74.00, according to a recent analyst note. The new target reflects the firm's positive outlook on the company's gene therapy programs, particularly for rare diseases.
Ultragenyx focuses on developing treatments for rare and ultra-rare genetic diseases. The company's pipeline includes several investigational therapies, such as UX111 for Sanfilippo syndrome type A and DTX401 for glycogen storage disease type Ia. Morgan Stanley's revised target suggests confidence in the potential of these programs.
As of the latest data, Ultragenyx's stock was trading around $60, indicating a potential upside of more than 20% from the new price target. The stock has been volatile over the past year, influenced by clinical trial results and regulatory updates.
Investors should note that price targets are analysts' opinions and not guarantees of future performance. The actual stock price may vary based on clinical outcomes, regulatory decisions, and market conditions.
